HC Wainwright & Co. Reiterates Buy on Galectin Therapeutics, Maintains $11 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.8%

Neg 0% Neu 89.8% Pos 0%

HC Wainwright & Co. analyst Matthew Keller reiterates Galectin Therapeutics (NASDAQ:GALT) with a Buy and maintains $11 price target.